MCM
KURA icon

Moore Capital Management’s Kura Oncology KURA Stock Holding History

Moore Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$163K – 419
2020
Q2 		$163K Buy
+10,000
New +$144K ﹤0.01% 242

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Moore Capital Management's KURA Position: Q3 2020 in Review

Moore Capital Management sold out of Kura Oncology (KURA) in Q3 2020, closing a stake of 10,000 shares — an estimated $163K sold.

Moore Capital Management first reported a position in KURA in Q2 2020 and held it in 1 quarter. The position peaked at $163K in Q2 2020. 162 funds tracked by Wall St. Rank hold KURA as of Q3 2020.

  • Moore Capital Management reported no remaining Kura Oncology position as of Q3 2020 after selling out during the quarter.
  • Moore Capital Management sold 10,000 Kura Oncology shares in Q3 2020, an estimated $163K.
  • Moore Capital Management first reported a position in Kura Oncology in Q2 2020 and held it in 1 quarter.
  • Moore Capital Management's Kura Oncology position peaked at $163K in Q2 2020.
  • 162 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2020.

Based on Moore Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.